Modeling Platinum-Induced Nephrotoxicity: A PK/TD Analysis of Calbindin and B2-Microglobulin Urinary Biomarkers

This webinar, presented by Avisek Ghirmire, explores the development of a population pharmacokinetic model of platinum following cisplatin treatment in cancer patients and its extension into a pharmacokinetic toxicodynamic framework.

A sequential modeling approach was applied to link platinum exposure with markers of kidney injury, resulting in a Population PKTD model designed to assess risk factors for platinum induced nephrotoxicity. Urinary biomarkers, including Calbindin and beta 2 microglobulin, were used to characterize renal toxicity and quantify the exposure response relationship.

The session discusses the model building strategy, key assumptions, and evaluation steps, as well as the clinical insights gained from the final PKTD model. Attendees will gain a deeper understanding of how integrated PK and toxicodynamic modeling can support risk assessment and inform safer use of cisplatin in oncology patients.